GT Medical Technologies completes oversubscribed $100M Series E
What's the deal? GT Medical Technologies, a Tempe, Arizona-based medical device company, has closed an oversubscribed $100M Series E equity financing. The round was led by new investor Viking Global InvestorsDealroom has a profile for this one. Try Dealroom →, with participation from existing backers MVM Partners, Gilde HealthcareDealroom has a profile for this one. Try Dealroom →, Evidity Health CapitalDealroom has a profile for this one. Try Dealroom →, Medtech Venture Partners, and FemHealth VenturesDealroom has a profile for this one. Try Dealroom →.
The funds will accelerate commercial and operational growth for GammaTile, the company's FDA-cleared bioresorbable radiotherapy implant used to treat operable brain tumours. Proceeds will also support a new randomised controlled trial in patients with glioblastomas.
Why now? The timing tracks directly to breakthrough clinical data. Last month, GT Medical Technologies released final results from its ROADS randomised controlled trial, which studied GammaTile in patients with newly diagnosed brain metastases. The data was selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) conference.
The numbers were striking: GammaTile reduced the risk of tumour recurrence by 93% and death at 12 months by 41% compared to standard of care. The 12-month tumour recurrence rate was 1.3% for GammaTile versus 15.4% for standard treatment. Twenty-four-month overall survival reached 61.7% with GammaTile, compared with 35.7% for standard of care.
GammaTile works by delivering targeted radiation immediately during brain tumour removal surgery — eliminating the typical delay between surgery and radiation that conventional approaches require for wound healing.
"This financing is validation of GammaTile's potential to be a standard of care treatment for operable brain tumors," said Per Langoe, chief executive officer at GT Medical Technologies.
What could go wrong? Medtech commercialisation is notoriously difficult. Convincing surgeons to adopt a new intraoperative device requires significant training and institutional buy-in. The company must also demonstrate that its trial results hold up across broader patient populations as it expands into glioblastoma treatment through its BRIDGES trial.
Regulatory and reimbursement hurdles remain. Even with strong clinical data, securing consistent insurance coverage across different healthcare systems can slow adoption.
The signal: Viking Global Investors, classified as an investment fund rather than a dedicated healthcare VC, leading a $100M medtech round underscores growing crossover investor appetite for clinical-stage medical devices with randomised controlled trial data. GT Medical Technologies sits at the late growth stage according to Dealroom, and this oversubscribed Series E — backed by a syndicate spanning life science specialists like MVM Partners and Gilde Healthcare alongside a generalist heavyweight — suggests the company is being positioned for a potential exit or public market transition as it pursues standard-of-care status in operable brain tumours.
Read more: prnewswire.com
